Coenzyme_A

Summary

Coenzyme_A (CHEMBL1213327) is a phase-3 clinical-stage small-molecule coenzyme; indicated across 2 conditions including hyperlipoproteinemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 767.5 Da · C21H36N7O16P3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1213327
Name	Coenzyme_A
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	87642
ChEBI	CHEBI:15346
Molecular formula	C21H36N7O16P3S
Molecular weight	767.5
InChIKey	RGJOEKWQDUBAIZ-IBOSZNHHSA-N

SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCS)O

IUPAC name: [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] hydrogen phosphate

ChEBI definition: A thiol comprising a panthothenate unit in phosphoric anhydride linkage with a 3’,5’-adenosine diphosphate unit; and an aminoethanethiol unit.

Pharmacological roles (ChEBI): coenzyme.

Other ChEBI roles (chemical / environmental): Escherichia coli metabolite, mouse metabolite.

Also known as: Coenzyme_a, Coash, Coenzyme a, Coenzyme A, CoASH, COENZYME_A, COENZYME-A, coenzyme-a

Patent coverage: 5,696 distinct patent families (10,084 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 9,011 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Histone acetyltransferase p300, Choline O-acetyltransferase, N-alpha-acetyltransferase 50, Histone acetyltransferase KAT2B, Histone acetyltransferase KAT5.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NAA50	6.81	Kd	156	nM	CHEMBL_ACT_20663962

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hyperlipoproteinemia	3	MONDO:0037748	MONDO:0037748

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01811082	PHASE3	COMPLETED	Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia
NCT01878227	PHASE3	COMPLETED	Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia
NCT01928342	PHASE2/PHASE3	UNKNOWN	The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia
NCT01645046	PHASE2	COMPLETED	The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).